5 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 7 points (0.0%) at 14,818 as of Tuesday, Sept. 3, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,623 issues advancing vs. 1,312 declining with 88 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is down 0.3%. Top gainers within the industry include Novartis ( NVS), up 2.2%, and GlaxoSmithKline ( GSK), up 1.6%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Regeneron Pharmaceuticals ( REGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Regeneron Pharmaceuticals is up $13.55 (5.6%) to $255.86 on average volume. Thus far, 449,130 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 765,000 shares. The stock has ranged in price between $245.98-$257.80 after having opened the day at $245.99 as compared to the previous trading day's close of $242.31.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $23.4 billion and is part of the health care sector. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Biogen Idec ( BIIB) is up $7.44 (3.5%) to $220.46 on average volume. Thus far, 594,315 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $213.05-$221.48 after having opened the day at $216.00 as compared to the previous trading day's close of $213.02.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $50.6 billion and is part of the health care sector. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Amgen ( AMGN) is up $1.55 (1.4%) to $110.49 on average volume. Thus far, 1.4 million shares of Amgen exchanged hands as compared to its average daily volume of 3.4 million shares. The stock has ranged in price between $110.04-$111.98 after having opened the day at $110.53 as compared to the previous trading day's close of $108.94.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $82.1 billion and is part of the health care sector. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is up $2.72 (1.9%) to $142.70 on average volume. Thus far, 1.2 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $141.65-$144.73 after having opened the day at $141.77 as compared to the previous trading day's close of $139.98.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $57.6 billion and is part of the health care sector. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.68 (1.1%) to $60.94 on average volume. Thus far, 3.6 million shares of Gilead exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $60.72-$61.60 after having opened the day at $60.90 as compared to the previous trading day's close of $60.27.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $92.3 billion and is part of the health care sector. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)